The effects of reboxetine and venlafaxine on ECG variables in depressed patients

Simple item page
dc.contributor.buuauthorEker, Salih Saygın
dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorCangür, Şengül
dc.contributor.buuauthorYuvanç, Uǧur
dc.contributor.buuauthorSarandöl, Aslı
dc.contributor.buuauthorKırlı, Selçuk
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.tr_TR
dc.contributor.researcheridQ-9477-2019tr_TR
dc.contributor.scopusid14019347700tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid8604063700tr_TR
dc.contributor.scopusid24391606100tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.date.accessioned2022-03-18T08:38:11Z
dc.date.available2022-03-18T08:38:11Z
dc.date.issued2011-03
dc.description.abstractObjective: Antidepressants exert distinct effects on cardiac autonomic nervous system function depending on their receptor profile; thus, different groups of antidepressants are expected to influence cardiac parameters in varying degrees. This study compares the effects of venlafaxine, a serotonin and noradrenaline reuptake inhibitor and reboxetine, a selective noradrenaline reuptake inhibitor, on ECG parameters and vital signs. Methods: The cardiac parameters and vital signs of 44 depressed patients were evaluated. The initial dose of venlafaxine XR was 75 mg/day and the dose was increased to 150 mg/day at the end of the 2(nd) week. Reboxetine was started at 4 mg/day and increased to 8 mg/day at the end of the 2(nd) week of the study. Electrocardiography (ECG) was performed and the PR, QRS, QT, and QTc intervals were measured both at the beginning and at the end of the trial, as were the vital signs. Results: The heart rate was significantly increased in the reboxetine group (Wilcoxon z=-3.510, p < 0.001). The ECG parameters did not demonstrate significant differences at the end of the trial in the venlafaxine group, whereas the QT interval was significantly shortened (Wilcoxon z=-2.157, p=0.031) and the QTc interval significantly prolonged (Wilcoxon z=-2.399, p=0.016) in the reboxetine group at the end of the trial. Diastolic blood pressure (supine) was significantly increased at the end of the trial (Wilcoxon z=-2.390, p=0.017) in the venlafaxine group. Conclusions: Since antidepressants have distinct receptor profiles,they may have varying effects on cardiac parameters. Reboxetine, a selective noradrenergic drug, is more likely to influence cardiac parameters than venlafaxine, a dual acting drug. Different groups of antidepressants, based on their mechanisms, of action should be studied more extensively with regard to their cardiac effects.en_US
dc.identifier.citationEker, S. S. vd.(2011). "The effects of reboxetine and venlafaxine on ECG variables in depressed patients". Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 21(1), 11-17.tr_TR
dc.identifier.endpage17tr_TR
dc.identifier.issn1017-7833
dc.identifier.issue1tr_TR
dc.identifier.scopus2-s2.0-79955634492tr_TR
dc.identifier.startpage11tr_TR
dc.identifier.urihttps://www.tandfonline.com/doi/pdf/10.5350/KPB-BCP201121103
dc.identifier.urihttp://hdl.handle.net/11452/25184
dc.identifier.volume21tr_TR
dc.identifier.wos000290364100003tr_TR
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherKüre İletişim Grubutr_TR
dc.relation.journalKlinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacologytr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subjectQTc intervalen_US
dc.subjectVenlafaxineen_US
dc.subjectReboxetineen_US
dc.subjectDepressionen_US
dc.subjectHeart rateen_US
dc.subjectHeart-rate-variabilityen_US
dc.subjectNorepinephrine reuptake inhibitoren_US
dc.subjectCoronary-artery diseaseen_US
dc.subjectTorsade-de-pointesen_US
dc.subjectQT intervalen_US
dc.subjectTricyclic antidepressantsen_US
dc.subjectMyocardial-infarctionen_US
dc.subjectSudden-deathen_US
dc.subjectSafetyen_US
dc.subjectDrugsen_US
dc.subject.emtreeHydroxyzineen_US
dc.subject.emtreeReboxetineen_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAntihypertensive therapyen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBody temperatureen_US
dc.subject.emtreeClinical evaluationen_US
dc.subject.emtreeComparative effectivenessen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDepressionen_US
dc.subject.emtreeDiastolic blood pressureen_US
dc.subject.emtreeDose responseen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeElectrocardiographyen_US
dc.subject.emtreeElectrocardiography monitoringen_US
dc.subject.emtreeHeart rateen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLow drug doseen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeOpen studyen_US
dc.subject.emtreePR intervalen_US
dc.subject.emtreeQRS complexen_US
dc.subject.emtreeQT intervalen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSingle blind procedureen_US
dc.subject.emtreeSleep disorderen_US
dc.subject.emtreeSystolic blood pressureen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeVital signen_US
dc.subject.scopusMorpholines; Reboxetine; Amino Alcoholsen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.titleThe effects of reboxetine and venlafaxine on ECG variables in depressed patientsen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus